NEW YORK (GenomeWeb) – The Bladder Cancer Advocacy Network (BCAN) and Paradigm today announced a partnership aimed at improving the genomic profiling of bladder cancer. 

The partners will collaborate on a large-scale genomic study that will also include participation by medical centers. The goal is to facilitate the development of new drug treatments for bladder cancer based on a better understanding of the genomic underpinnings of the disease. 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

A federal grand jury has indicted Elizabeth Holmes and Ramesh Balwani for alleged wire fraud in conjunction with their activities at Theranos.

A direct-to-consumer genetic testing company sent out used spit kits, CNBC reports.

Nature News reports that some developers are nervous about GitHub's acquisition by Microsoft.

In PLOS this week: comparison of commercial bisulfite kits, new method to predict essential proteins, and more

Jun
21
Sponsored by
Roche

This webinar will provide a detailed look at how a genomics lab implemented next-generation sequencing (NGS) liquid biopsy assays into its in-house clinical research program.

Jun
26
Sponsored by
Lexogen

This webinar outlines a study that sought to characterize the landscape of alternative polyadenylation (APA) in the lung cancer transcriptome in order to gain insight into the role of APA in cancer progression.

Jun
27
Sponsored by
Roche

This webinar will present data from the FLAURA trial and show the clinical utility of liquid biopsy in identifying non-small-cell lung cancer (NSCLC) patients who may benefit from targeted TKI therapies. 

Jul
10
Sponsored by
Qiagen

This webinar offers a look at how an advanced genetics laboratory implemented and validated a commercial bioinformatics system to help scale its operations.